Posted on November 15, 2017 by Sitemaster
On a CureTalks conversation earlier today with Dr. Carl June of the University of Pennsylvania (UPenn), we learned that his team had very recently treated two men with metastatic, castration-resistant prostate cancer (mCRPC) using chimeric antibody receptor T-cell therapy (CAR-T). … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: antibody, CAR-T, chimeric, receptor, T-cell | 9 Comments »
Posted on November 7, 2017 by Sitemaster
On November 15, our friends at CureTalks will hold a telecon on which there will be a discussion about the current and potential future uses of CAR-T in the treatment of cancer with Prof. Carl June of the University of Pennsylvania. … READ MORE …
Filed under: Drugs in development | Tagged: antigen, CAR-T, chimeric, receptor, T-cell, therapy | Leave a comment »
Posted on February 28, 2017 by Sitemaster
As yet, there has been no serious clinical exploration of whether the new types of CAR-T treatment can be applied to patients with either prostate cancer or any other form of solid tumor. … READ MORE …
Filed under: Drugs in development | Tagged: antigen, CAR-T, chimeric, receptor, therapy | 2 Comments »
Posted on October 16, 2014 by Sitemaster
An article in today’s issue of the New England Journal of Medicine reports data from a Phase II trial of CART therapy in the treatment of patients with acute lymphoblastic leukemia or ALL (an aggressive and difficult to treat form of cancer). This is arguably one of the most exciting papers on the treatment of cancer in the past 50+ years. … READ MORE …
Filed under: Uncategorized | Tagged: antigen, CART, chimeric, CTL019, leukemia, T-cell | Leave a comment »